ArticleCancer medicine2026
Influence of Hypertension Management on Survival in Patients With Metastatic Breast Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough nearly half of women with metastatic breast cancer (mBC) have hypertension, it is unclear whether hypertension management improves survival. We examined the influence of pharmacologic hypertension management on all-cause and breast cancer-specific mortality in patients with mBC.
methodsWe conducted a longitudinal cohort study of 1332 female patients with de novo mBC diagnosed 2008-2020, followed through 2021. We calculated person-year (PY) rates of all-cause and breast cancer mortality by use of antihypertensives (monotherapy or polytherapy [one vs. multiple drug classes]). Multivariable Cox regression was used to estimate the association between antihypertensives and mortality.
resultsOverall, 48.4% of patients with mBC had hypertension, which was greatest in Black women (64.6%). During follow-up, 52.9% were treated with antihypertensive medications (20.3% monotherapy; 32.5% polytherapy). All-cause mortality rates were lower in the polytherapy (21.4/100 PY) versus monotherapy (28.5/100 PY) group. All-cause mortality risk was 38% lower (adjusted HR = 0.62; 95% CI: 0.47-0.82) in the polytherapy group vs. monotherapy. This protection was significantly greater in Hispanic patients (HR = 0.40; 95% CI: 0.20-0.84) and suggested in Black patients (HR = 0.48; 95% CI: 0.22-1.05). Similarly, breast cancer mortality was lower in those treated with polytherapy versus monotherapy, particularly those with good medication adherence (HR = 0.43; 95% CI: 0.24-0.77).
conclusionIn patients with mBC, all-cause mortality risk was lower among those treated with antihypertensive polytherapy versus monotherapy, with the greatest risk attenuation seen among Hispanic women. Additional prospective studies are needed to examine comorbidity management strategies that may help patients with mBC extend life, particularly including women of color.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.